These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8928070)

  • 1. [The prognostic criteria in the primary myelodysplastic syndrome].
    Tsvetaeva NV; Zavadenko MA; Popov VIu; Glasko EN; Gorodnicheva VF; Levina AA; Pochtar' ME; Vinogradova OIu; Alisova AM; Frank GA; Khoroshko ND
    Ter Arkh; 1996; 68(7):37-42. PubMed ID: 8928070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ringed sideroblasts in primary myelodysplasia. Leukemic propensity and prognostic factors.
    Vandermolen L; Rice L; Rose MA; Lynch EC
    Arch Intern Med; 1988 Mar; 148(3):653-6. PubMed ID: 3341866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
    Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
    Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
    Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
    J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
    Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; O'Brien S; Kontoyiannis DP; Giles F; Zhou X; Lim J; Bekele BN; Faderl S; Cortes J; Pierce S; Leitz GJ; Raad I; Estey E
    Cancer; 2004 Feb; 100(3):568-73. PubMed ID: 14745874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome].
    Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA
    Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
    Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.
    Neumann F; Gattermann N; Barthelmes HU; Haas R; Germing U
    Leuk Res; 2009 Feb; 33(2):232-6. PubMed ID: 18639338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.
    Breccia M; Mancini M; Nanni M; D'Elia GM; Carmosino I; Latagliata R; Sarlo C; Mandelli F; Alimena G
    Leuk Res; 2005 Jan; 29(1):33-9. PubMed ID: 15541472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution.
    Balduini CL; Guarnone R; Pecci A; Centenara E; Invernizzi R; Ascari E
    Haematologica; 1999 Jan; 84(1):12-6. PubMed ID: 10091387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What does apoptosis have to do with clinical features in myelodysplastic syndrome?
    Ramos F; Fuertes-Núñez M; Suárez-Vilela D; Fernández-López A
    Haematologica; 2002 Apr; 87(4):381-91. PubMed ID: 11940482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic syndrome: a review of 35 patients.
    Bursztyn M; Douer D; Ramot B
    Isr J Med Sci; 1987 Nov; 23(11):1140-4. PubMed ID: 3436796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.
    Yue G; Hao S; Fadare O; Baker S; Pozdnyakova O; Galili N; Woda BA; Raza A; Wang SA
    Leuk Res; 2008 Apr; 32(4):553-8. PubMed ID: 17888511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
    Wong R; Shahjahan M; Wang X; Thall PF; De Lima M; Khouri I; Gajewski J; Alamo J; Couriel D; Andersson BS; Donato M; Hosing C; Komanduri K; Anderlini P; Molldrem J; Ueno NT; Estey E; Ippoliti C; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):108-14. PubMed ID: 15682071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.
    Okamoto T; Kanamaru A; Shimazaki C; Motoji T; Takemoto Y; Takahashi M; Fukushima T; Takeshita A; Kusumoto GS; Kishimoto Y; Yorimitsu S; Tsukuda K; Uike N; Arima N; Ohno R
    Int J Hematol; 2000 Aug; 72(2):200-5. PubMed ID: 11039669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
    Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
    Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
    Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
    Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.